Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) EBIT: HK$-373.8 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02591 Guangzhou Innogen Pharmaceutical Group Co Ltd HKSE:02591
9 GF Score
Price HK$7.60
! 2 Warning Signs
View Full Analysis

What is Guangzhou Innogen Pharmaceutical Group Co EBIT?

Guangzhou Innogen Pharmaceutical Group Co HKSE:02591 +5.26% 9 EBIT is HK$-373.8 Mil as of Dec. 2025. GuruFocus rates HKSE:02591 with a GF Score™ of 9/100. The stock has 2 warning signs investors should review.

Guangzhou Innogen Pharmaceutical Group Co's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was HK$-240.4 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-373.8 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Guangzhou Innogen Pharmaceutical Group Co's annualized ROC % for the quarter that ended in Dec. 2025 was -199.30%. Guangzhou Innogen Pharmaceutical Group Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -1,274.53%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Guangzhou Innogen Pharmaceutical Group Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -17.03%.

Guangzhou Innogen Pharmaceutical Group Co  (HKSE:02591) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Guangzhou Innogen Pharmaceutical Group Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-482.946 * ( 1 - 0% )/( (135.896 + 348.741)/ 2 )
=-482.946/242.3185
=-199.30 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1026.265 - 217.733 - ( 802.279 - max(0, 264.212 - 936.848+802.279))
=135.896

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1735.535 - 310.35 - ( 1330.92 - max(0, 557.427 - 1633.871+1330.92))
=348.741

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Guangzhou Innogen Pharmaceutical Group Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-480.778/( ( (36.584 + max(-139.49, 0)) + (38.86 + max(-208.057, 0)) )/ 2 )
=-480.778/( ( 36.584 + 38.86 )/ 2 )
=-480.778/37.722
=-1,274.53 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(9.399 + 40.465 + 28.379) - (217.733 + 0 + 0)
=-139.49

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6.14 + 128.083 + 45.795) - (310.35 + 0 + 77.725)
=-208.057

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Guangzhou Innogen Pharmaceutical Group Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-373.791/2194.545
=-17.03 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guangzhou Innogen Pharmaceutical Group Co EBIT Related Terms

Guangzhou Innogen Pharmaceutical Group Co EBIT Historical Data

* Premium members only.

The historical data trend for Guangzhou Innogen Pharmaceutical Group Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guangzhou Innogen Pharmaceutical Group Co EBIT Chart

Guangzhou Innogen Pharmaceutical Group Co Annual Data
Trend Dec23 Dec24 Dec25
EBIT
-799.62 -185.58 -375.22

Guangzhou Innogen Pharmaceutical Group Co Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
EBIT 0.00 -80.10 -106.14 -133.40 -240.39

HKSE:02591 vs VRTX, REGN, RVMD: EBIT Comparison

For the Biotechnology subindustry, Guangzhou Innogen Pharmaceutical Group Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Guangzhou Innogen Pharmaceutical Group Co EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Guangzhou Innogen Pharmaceutical Group Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Guangzhou Innogen Pharmaceutical Group Co's EV-to-EBIT falls into.


HKSE:02591
9GF Score
Guangzhou Innogen Pharmaceutical Group Co Ltd HKSE:02591
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guangzhou Innogen Pharmaceutical Group Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-373.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of HK$-373.8 Mil mean?
Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) has a EBIT of HK$-373.8 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Guangzhou Innogen Pharmaceutical Group Co.
Is Guangzhou Innogen Pharmaceutical Group Co's EBIT too high?
Guangzhou Innogen Pharmaceutical Group Co's current EBIT is HK$-373.8 Mil. Overall, Guangzhou Innogen Pharmaceutical Group Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Innogen Pharmaceutical Group Co's EBIT compare to VRTX and REGN?
Guangzhou Innogen Pharmaceutical Group Co's EBIT of HK$-373.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Guangzhou Innogen Pharmaceutical Group Co. Guangzhou Innogen Pharmaceutical Group Co's current EBIT is HK$-373.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Innogen Pharmaceutical Group Co stock overvalued right now?
Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) has a current EBIT of HK$-373.8 Mil. The current EBIT is HK$-373.8 Mil. Guangzhou Innogen Pharmaceutical Group Co's overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591), the current EBIT is HK$-373.8 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Guangzhou Innogen Pharmaceutical Group Co Business Description

Address No. 2 Tengfei Second Street, Room 409, Building H Self-numbered Creative Building, China-Singapore Guangzhou Knowledge City, Huangpu District, Guangdong Province, Guangzhou, CHN
Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize, a humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates namely YN014, YN401, YN209, YN202,YN203 targeting diabetes and other metabolic diseases.
9GF Score

Get the complete analysis for HKSE:02591

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$7.60
Price